Freddy E Escorcia 
Struggling to translate a #radiopharmaceuticals 101 talk from English to Spanish.
It's one thing to shoot the breeze, but a whole other thing to speak on "quelantes," "radionúclidos metálicos," "imagenología" and "marcadores radioactivos" 😬😅
🚨 Fellow #radiotheranostics nerds 🚨
Prof. Tim Witney and I are launching a Collection focused on this very topic for NPJ Imaging
Please considering submitting! Site is live!
🚨Hot off the presses🚨
Colleagues in Netherlands & Germany evaluated 68Ga-peptide specific to GPC3 in patients w #HCC.
✅Uptake in HCC and hepatoblastoma lesions
💡Heterogeneity of GPC3 expression in HCC
💡Gastric fundus uptake, but likely cleared over time
🚨New #radiopharmaceuticals imaging study out of The Netherlands🚨
HER2 PET can identify metastatic breast cancer with IHC-defined HER2-negative and low lesions.
PET can define the heterogeneity of target expression throughout a patient.
Happy galley proofs day to those who celebrate!!!
Stay tuned for a new paper that describes not one but *two* to methods to yield site-specifically conjugated small proteins labeled with [18F]AlF for fluorine-18-based positron emission tomograpy (PET) imaging.
It’s certainly a bit anachronistic, but there’s something to be said for seeing your work in print.
In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together.
ACR–ACNM–ARS–ASTRO–SNMMI Practice Parameter for the... : American Journal of Clinical Oncology
t is intended to serve as a resource for appropriately trained and licensed physicians who perform therapeutic procedures with unsealed sources, referred to in the document using the more inclusive terminology of radiopharmaceuticals, for which a written directive is required for authorized users under NRC 10 CFR 35.300. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the American Radium Society. Results: This practice parameter addresses the overall role of the applicable physician-authorized user, Qualified Medical Physicist, and other specialized personnel involved in the delivery of radiopharmaceutical therapy. Therapeutic radiopharmaceuticals include those administered as elemental radioactive isotopes (radionuclides) or the radioactive element incorporated into a targeting molecule (ligand) by one or more chemical bonds. This document provides guidance regarding general principles of radionuclide therapies and indications of various alpha, beta, gamma, and mixed emission agents with references to several recent practice parameters on new and commonly performed radiopharmaceutical therapies. Conclusions: This document addresses clinical circumstances, elements of available agents, and the qualifications and responsibilities of various members of the radiation care team, specifications of consultation and other clinical documentation, post-therapy follow-up, radiation safety precautions, elements of quality control and improvement programs, infection control, and patient education to ensure optimal patient care and safety when utilizing radiopharmaceuticals....
Our PhD student Stan *crushed* his presentation and Q&A at #ASTRO23
So lucky to get to work with such amazing trainees at the NCI!
Fun fact: Stan has already gotten an invite to present his science at ASTRO--an achievement that's eluded me thus far!
Excellent editorial by experts in #radiopharmaceuticals therapy regarding feasibility and need for personalized/individualized dosimetry to optimize therapeutic index in patients.
https://doi.org/10.1007/s00259-023-06420-z
Closing statement certainly resonates!
